ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Updated Phase 2 data evaluating ZYNLONTA^® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69%

CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment

Read more at prnewswire.com